The ‘Peptide for Life’ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

TY - JOUR

T1 - The ‘Peptide for Life’ Initiative

T2 - a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

AU - Bayes-Genis, Antoni

AU - Januzzi, James L.

AU - Richards, A. Mark

AU - Arfsten, Henrike

AU - de Boer, Rudolf A.

AU - Emdin, Michele

AU - González, Arantxa

AU - Jaarsma, Tiny

AU - Jhund, Pardeep S.

AU - Mueller, Christian

AU - Núñez, Julio

AU - Rossignol, Patrick

AU - Milinkovic, Ivan

AU - Rosano, Giuseppe M.C.

AU - Coats, Andrew

AU - Seferovic, Petar

N1 - Funding Information: : A.B.G. reports grants and personal fees from AstraZeneca, Abbott, Vifor, Boehringer Ingelheim, Novartis, Roche Diagnostics and Critical Diagnostics. J.L.J. is a trustee of the American College of Cardiology, a board member of Imbria Pharmaceuticals, has received grant support from Applied Therapeutics, Innolife, Novartis Pharmaceuticals and Abbott Diagnostics, consulting income from Abbott, Janssen, Novartis, and Roche Diagnostics, and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Amgen, Bayer, CVRx, Janssen, MyoKardia and Takeda. A.M.R. declares grants (including support in kind) and/or personal fees (researcher, speaker, advisory board member) from Roche Diagnostics, Abbott Laboratories, Thermo Fisher, Boston Scientific, Novartis, AstraZeneca, Sphingotec, Bayer and Critical Diagnostics. The UMCG, which employs R.A.d.B., has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. R.A.d.B. received speaker fees from Abbott, AstraZeneca, Bayer, Novartis, and Roche. P.S.J. is an employer of the University of Glasgow and has been remunerated by Novartis, Novo Nordisk and AstraZeneca for his work on clinical trials and he has received speakers fees and/or advisory board fees from Novartis, AstraZeneca, Boehringer Ingelheim and grants from Boehringer Ingelheim. C.M. has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the KTI, the European Union, the University of Basel, the University Hospital Basel, Abbott, Beckman Coulter, BRAHMS, Idorsia, Novartis, Ortho Clinical Diagnostics, Quidel, Roche, Siemens, Singulex, Sphingotec, as well as speaker honoraria/consulting honoraria from Acon, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Idorsia, Novartis, Osler, Roche, and Sanofi outside of the submitted work. J.N. reports speaker fees and/or advisory board fees from AstraZeneca, Novartis, Vifor Pharma, Boehringer Ingelheim, Novo Nordisk, Rovi, Bayer, and Pfizer. P.R. reports consulting for Bayer, G3P, Idorsia, and KBP; honoraria from Ablative Solutions, AstraZeneca, Bayer, Boehringer Ingelheim, Corvidia, CVRx, Fresenius, Grunenthal, Novartis, Novo Nordisk, Relypsa Inc., a Vifor Pharma Group Company, Sanofi, Sequana Medical, Servier, Stealth Peptides, and Vifor Fresenius Medical Care Renal Pharma; co‐founder: CardioRenal. A.C. declares having received honoraria and/or lecture fees from AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, Novartis, Nutricia, Servier, Vifor, Abbott, Actimed, Arena, Cardiac Dimensions, Corvia, CVRx, Enopace, ESN Cleer, Faraday, Gore, Impulse Dynamics, Respicardia. All other authors have nothing to disclose. Conflict of interest

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85110346515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85110346515&partnerID=8YFLogxK

U2 - 10.1002/ejhf.2293

DO - 10.1002/ejhf.2293

M3 - Article

C2 - 34231321

AN - SCOPUS:85110346515

SN - 1388-9842

VL - 23

SP - 1432

EP - 1436

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 9

ER -